Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2; there is no change to the study content, eligibility, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedPublication notes now indicate that PubMed publications are automatically filled from PubMed and may not be about the study, and the revision label has been updated to v3.3.1 from v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoval of the funding/operational status notice; the page continues to display the study details, eligibility criteria, and study plan.SummaryDifference0.4%

- Check43 days agoChange DetectedThe update shows revised last update timestamps and minor layout adjustments; core study details (title, conditions, eligibility criteria, and outcomes) are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedUpdate introduces version v3.2.0 and a government-operating status notice; it also removes the genetic resource for B-cell chronic lymphocytic leukemia.SummaryDifference5%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.